Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study

Authors: Riveline, JP., Vergés, B., Detournay, B., Picard, S., Benhamou, PY., Bismuth, E., Bordier, L., Jeandidier, N., Joubert, M., Roussel, R., Sola-Gazagnes, A., Bonnefond, A., Clavel, S., Velayoudom, FL., Beltrand, J., Hanaire, H., Fontaine, P., Thivolet, C., Servy, H., Tubiana, S., Lion, S., Gautier, Jean-François, Larger, Etienne, Vicaut, E., Sablone, L., Fagherazzi, G., Cosson, E.

Source: In Diabetes & Metabolism May 2022 48(3)

An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes

Authors: Reach G, Benarbia L, Benhamou PY, Delemer B, Dubois S, Gouet D, Guerci B, Jeandidier N, Lachgar K, Le Pape G, Leroy R, Masgnaux JH, Raclet P, Reznik Y, Riveline JP, Schaepelynck P, Vambergue A, Vergès B

Source: Patient Preference and Adherence, Vol Volume 16, Pp 1333-1350 (2022)

Subject Terms: type 2 diabetes, adherence, support programs, typology, personality traits, clinical outcomes, patients’ expectations, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.dovepress.com/an-unsafesafe-typology-in-people-with-type-2-diabetes-bridging-patient-peer-reviewed-fulltext-article-PPA; https://doaj.org/toc/1177-889X

Access URL: https://doaj.org/article/95f679704f194453a42364c7a9d89a16

Liraglutide Increases the Catabolism of Apolipoprotein B100—Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression

Authors: Vergès, B., Duvillard, L., de Barros, J. P. Pais, Bouillet, B., Baillot-Rudoni, S., Rouland, A., Petit, J. M., Degrace, P., Demizieux, L.

Source: Diabetes care. 44(4):1027-1037

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN626163202&indx=1&recIds=ETOCRN626163202

Thyroïdites : où en est-on en 2019 ?

Alternate Title: Thyroiditis: What's new in 2019? (English)

Authors: Rouland, A., Buffier, P., Petit, J.-M., Vergès, B., Bouillet, B. ^*

Source: In La revue de médecine interne June 2020 41(6):390-395

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

Authors: Capehorn, M.S., Catarig, A.-M., Furberg, J.K., Janez, A., Price, H.C., Tadayon, S., Vergès, B., Marre, M.

Source: In Diabetes & Metabolism April 2020 46(2):100-109

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion

Authors: Rouland A, Bouillet B, Legris P, Simoneau I, Petit JM, Vergès B

Source: Clinical Pharmacology: Advances and Applications, Vol Volume 13, Pp 33-37 (2021)

Subject Terms: nesidioblastosis, hypoglycemia, pasireotide lar, diazoxide, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.dovepress.com/successful-control-of-hypoglycemia-with-pasireotide-lar-in-a-patient-w-peer-reviewed-article-CPAA; https://doaj.org/toc/1179-1438

Access URL: https://doaj.org/article/d8264b66157e4ce1bdcf3214ccab41cf

Mécanismes possibles des effets bénéfiques cardiovasculaires des inhibiteurs SGLT2

Alternate Title: Possible mechanisms of cardiovascular benefits of SGLT2 inhibitors (English)

Authors: Vergès, B. ^{1, 2, *}

Source: In Archives of Cardiovascular Diseases Supplements December 2019 11 Supplement 4:S18-S22

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings

Authors: Guerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., Vergès, B.

Source: In Diabetes & Metabolism December 2019 45(6):528-535

Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction

Authors: Benalia, M., Zeller, M., Mouhat, B., Guenancia, C., Yameogo, V., Greco, C., Yao, H., Maza, M., Vergès, B., Cottin, Y.

Source: In Diabetes & Metabolism October 2019 45(5):446-452

High efficacy of screening for diabetes and prediabetes in cardiac rehabilitation after an acute coronary syndrome (ACS). The REHABDIAB study

Authors: Vergès, B., Patois-Vergès, B., Goueslard, K., Cottenet, J., Nguyen, A., Tatulashvili, S., Blonde, M.-C., Quantin, C.

Source: Diabetes & metabolism. 45(1):79-82

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100075093799.0x000001&indx=1&recIds=ETOCvdc_100075093799.0x000001

Hypertriglyceridemia in diabetes

Authors: Vergès, B.

Source: Correspondances en MHDN. 24(6):201-206

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN625552702&indx=1&recIds=ETOCRN625552702

Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms

Authors: Roger, C., Buch, C., Muller, T., Leemput, J., Demizieux, L., Passilly-Degrace, P., Cinar, R., Iyer, M. R., Kunos, G., Vergès, B.

Source: Diabetes. 69(10):2120-2132

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN624813817&indx=1&recIds=ETOCRN624813817

Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

Authors: Capehorn, M.S., Catarig, A.-M., Furberg, J.K., Janez, A., Price, H.C., Tadayon, S., Vergès, B., Marre, M.

Source: Diabetes & metabolism. 46(2):100-109

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100115228715.0x000001&indx=1&recIds=ETOCvdc_100115228715.0x000001

Physiopathologie de la dyslipidémie du diabète de type 2 : nouvelles perspectives

Alternate Title: Pathophysiology of type 2 diabetes dyslipidemia: New perspectives (English)

Authors: Vergès, B. ^*

Source: In Médecine des maladies métaboliques March 2019 13(2):140-146

Bénéfices cardiovasculaires et rénaux des inhibiteurs de SGLT2 : mécanismes de la protection

Alternate Title: Cardiovascular and renal benefits of SGLT2 inhibitors: Protective mechanisms (English)

Authors: Vergès, B. ^*, Hadjadj, S.

Source: In Médecine des maladies métaboliques March 2019 13 Supplement 1:S25-S30

Enquête sur la prise en charge des patients diabétiques de type 2 par les médecins généralistes en Bourgogne. Implications pour l’enseignement post-universitaire

Alternate Title: Treatment of Type 2 diabetes by general practitioners in Burgundy survey. Implication for postgraduate education (English)

Authors: Mandrapylia, A., Vergès, B.

Source: In Médecine des maladies métaboliques October 2018 12(6):520-526

High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry

Authors: Angoulvant, D., Béliard, S., Benlian, P., Boileau, C., Boccara, F., Bruckert, E., Cariou, B., Carreau, V., Carrié, A., Charrière, S., Di Filippo, M., Ducluzeau, P.H., Dulong, S., Durlach, V., Farnier, M., Ferrari, E., Ferrières, J., Gallo, A., Girardet, J.P., Hankard, R., Krempf, M., Lalau, J.D., Lefort, B., Lemale, J., Moulin, P., Paillard, F., Peretti, N., Pradignac, A., Pucheu, Y., Rabès, J.P., Saheb, S., Sultan, A., Tounian, P., Valéro, R., Varret, M., Vergès, B., Yelnik, C., Ziegler, O., Béliard, Sophie, Boccara, Franck, Cariou, Bertrand, Carrié, Alain, Collet, Xavier, Farnier, Michel, Ferrières, Jean, Krempf, Michael, Peretti, Noël, Rabès, Jean-Pierre, Varret, Mathilde, Vimont, Alexandre, Charrière, Sybil, Bruckert, Eric

Source: In Atherosclerosis October 2018 277:334-340

Identification des répondeurs au traitement par exénatide ou liraglutide : résultats de deux études en vie réelle

Alternate Title: Identification of responders to treatment with exenatide or liraglutide: Results of two real-life studies (English)

Authors: Groza, L., Caussy, C., Moulin, P., Ziegler, O., Fay, R., Raccah, D., Vergès, B., Delemer, B., Picard, S., Gourdy, P., Guerci, B.

Source: In Médecine des maladies métaboliques February 2018 12(1):62-68

Type A competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes

Authors: Chauvet-Gélinier, J.-C., Mosca-Boidron, A.-L., Lemogne, C., Ragot, S., Forestier, N., Callegarin, D., Allard, C., Rebaï, A., Bouillet, B., Ponavoy, E., Simoneau, I., Petit, J.-M., Bondolfi, G., Callier, P., Trojak, B., Bonin, B., Vergès, B.

Source: Diabetes & metabolism. 45(6):582-585

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100092596768.0x000001&indx=1&recIds=ETOCvdc_100092596768.0x000001

Traitement de la stéatose et de la stéatohépatite non alcoolique par les traitements antidiabétiques

Alternate Title: Treatment of NAFLD and NASH with antidiabetic therapies (English)

Authors: Vergès, B.

Source: In Médecine des maladies métaboliques December 2017 11(8):697-701